DEF: CooperCompanies Aims for Growth and Impact: 2025 Proxy Statement Highlights Strategic Priorities and Executive Compensation

CooperCompanies' 2025 proxy statement outlines the company's strategic focus on market share gains, profitability, and long-term growth, while also detailing executive compensation practices and corporate governance policies.

Summary

• CooperCompanies' 2025 proxy statement details the agenda for the annual meeting of stockholders, including the election of directors, an amendment to the certificate of incorporation, ratification of the independent auditor, and an advisory vote on executive compensation.
• The company reported revenue of $3.90 billion for fiscal year 2024, an 8% increase from the previous year.
• GAAP diluted EPS was $1.96, while non-GAAP diluted EPS was $3.69.
• The company's total stockholder return was 34.31%.
• CooperVision is the #1 contact lens company based on the number of wearers.
• CooperSurgical expanded its portfolio through strategic acquisitions.
• The company is focused on increasing the availability of innovative products, expanding manufacturing capacity, optimizing technology investments, and developing new products.
• Executive compensation is tied to financial performance and stockholder return outcomes, with a significant portion of executive pay being performance-based.
• The board is committed to good governance and business practices, with a focus on risk oversight and corporate social responsibility.

Sentiment

Score: 8

Explanation: The document presents a positive outlook for the company, highlighting strong financial performance, strategic initiatives, and a commitment to good governance. The tone is optimistic and confident.

Positives

• The company achieved significant revenue growth in fiscal year 2024.
• CooperVision is the #1 contact lens company based on the number of wearers.
• Executive compensation is strongly linked to performance.
• The company has a strong focus on corporate governance and risk management.
• The company is committed to corporate social responsibility and sustainability.
• The company has a compensation recovery (clawback) policy applicable to executive officer incentive compensation.

Risks

• The company faces competitive, legal, regulatory, operational, and financial risks.
• The company's success depends on its ability to attract and retain qualified executive officers.
• The company's performance is subject to market conditions and industry trends.

Future Outlook

The company is focused on taking market share, driving profitability, and executing on its strategic priorities to increase impact and drive value.

Management Comments

• We launched into 2025 with a new shared purpose for the company: Helping People Experience Life's Beautiful Moments.
• We are uniting our 16,000+ employees under this shared purpose and hope that you, our stockholders, also take great pride in the global impact you enable.
• The future is bright at Cooper.

Industry Context

CooperCompanies operates in the global medical device industry, specifically focusing on contact lenses and women's healthcare. The company's performance is influenced by factors such as market share, product innovation, and strategic acquisitions.

Comparison to Industry Standards

• The document mentions several companies in the Healthcare Equipment, Healthcare Supplies, and Life Sciences Tools and Services industries as part of CooperCompanies' peer group for compensation benchmarking.
• These companies include Agilent Technologies, Illumina, Align Technology, Masimo Corporation, Bausch + Lomb Corporation, ResMed Inc., Bio-Rad Laboratories, Revvity, Inc., Charles River Laboratories International, Inc., STERIS PLC, DENTSPLY SIRONA Inc., Teleflex Incorporated, DexCom, Inc., Waters Corporation, Edwards Lifesciences Corporation, and Zimmer Biomet Holdings, Inc.
• The document does not provide a direct comparison of CooperCompanies' financial results to these specific companies, but it does state that the company's executive compensation is designed to be competitive with these peers.

Related Party Transactions

• We have determined that there were no related party transactions requiring disclosure during the 2024 fiscal year.

Stakeholder Impact

• The company's performance and strategic initiatives are expected to benefit stockholders through increased value and returns.
• Employees are united under a shared purpose and benefit from investments in employee development.
• Customers benefit from the availability of innovative products and services.
• The company's commitment to sustainability and social responsibility benefits communities and the environment.

Next Steps

• Elect seven directors to the Board.
• Approve an amendment to the Second Restated Certificate of Incorporation.
• Ratify the appointment of KPMG LLP as the independent registered public accounting firm.
• Approve, on a non-binding, advisory basis, the compensation of the Named Executive Officers.

Key Dates

Keywords

executive compensation, corporate governance, financial performance, contact lenses, medical devices, CooperCompanies, CooperVision, CooperSurgical